proxyvotesnow.com
23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › BIOXCEL THERAPEUTICS INC. › 2023-2024

BIOXCEL THERAPEUTICS INC. 2023-2024 Proxy Voting Records

At BIOXCEL THERAPEUTICS INC.'s shareholder meeting held June 10, 2024, in the 2023-2024 proxy season, 94 asset managers reported how they voted in their SEC Form N-PX filings, covering 888 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory (non-binding) basis, of the compensation of the Company's named… — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BIOXCEL THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2024.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BIOXCEL THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 8Reported items
  • 94Asset managers
  • 888Fund votes
  • June 10, 2024Meeting date

Results at a glance

Meeting of June 10, 2024: 7 items on BIOXCEL THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024: 1 approved · 6 without a stated outcome.

Material dissent

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024

Explore BIOXCEL THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by BIOXCEL THERAPEUTICS INC.

These tallies are BIOXCEL THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BIOXCEL THERAPEUTICS INC. — official shareholder meeting results, meeting held June 10, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Vimal Mehta, Ph.D. 16,490,409---- 2,066,7017,552,611 89%Not verified—
Elect Director: Peter Mueller, Ph.D. 13,702,818---- 4,854,2927,552,611 74%Not verified—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 25,725,808262,875121,038 --0 99%Not verified—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers ("Say-on-Pay Vote") 14,391,9434,123,99741,170 --7,552,611 78%Not verified—
5. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to authorize additional shares of common stock from 100,000 to 200,000 21,154,4624,882,35372,906 --0 81%Not verified—
6. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to provide for exculpation of officers to the extent permitted by the General Corporation Law of the State of Delaware 17,766,354733,97256,784 --7,552,611 96%Not verified—
7. Approval of an adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal Nos. 5 and/or 6 15,516,2132,998,96141,936 --7,552,611 84%Approved—

Source: BIOXCEL THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2024 — read the filing on EDGAR.

How asset managers voted at the BIOXCEL THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 94 asset managers that disclosed a BIOXCEL THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BIOXCEL THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Peter Mueller, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 13,702,818WITHHELD: 4,854,292
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class III Directors: Peter Mueller, Ph.D.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Mueller, Ph.D.”): 13,702,818 for, 4,854,292 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 433,648 for, 1,499,029 withheld, 7,436 abstained.

FORWITHHOLD
FOR: 433,648ABSTAIN: 7,436WITHHOLD: 1,499,029
Largest asset managers voting on “Election of Class III Directors: Peter Mueller, Ph.D.” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity135,5920 0427,339Mixed
Columbia Threadneedle00 0505,290Withhold
Vanguard288,2440 00For
BlackRock00 0262,535Withhold
Charles Schwab00 0129,169Withhold
Equitable00 036,056Withhold
HC CAPITAL TRUST00 029,713Withhold
QUANTITATIVE MASTER SERIES LLC00 023,064Withhold
Northern Trust00 022,823Withhold
Lincoln Financial00 015,930Withhold
AIG/SunAmerica00 010,315Withhold
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds00 07,314Withhold
State Street00 06,383Withhold
Pacific Life00 06,238Withhold
John Hancock00 4,0800Abstain
Invesco00 04,008Withhold
SEI00 03,900Withhold
Bridge Builder Trust00 3,3560Abstain
Principal00 02,494Withhold
Voya00 02,197Withhold
T. Rowe Price1,4300 00For
Calvert00 01,350Withhold
ProShares00 0813Withhold
Morgan Stanley00 0654Withhold

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

2. Elect Director: Vimal Mehta, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 16,490,409WITHHELD: 2,066,701
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class III Directors: Vimal Mehta, Ph.D.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Vimal Mehta, Ph.D.”): 16,490,409 for, 2,066,701 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,512,774 for, 427,339 withheld.

FORWITHHOLD
FOR: 1,512,774WITHHOLD: 427,339
Largest asset managers voting on “Election of Class III Directors: Vimal Mehta, Ph.D.” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity135,5920 0427,339Mixed
Columbia Threadneedle505,2900 00For
Vanguard288,2440 00For
BlackRock262,5350 00For
Charles Schwab129,1690 00For
Equitable36,0560 00For
HC CAPITAL TRUST29,7130 00For
QUANTITATIVE MASTER SERIES LLC23,0640 00For
Northern Trust22,8230 00For
Lincoln Financial15,9300 00For
AIG/SunAmerica10,3150 00For
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds7,3140 00For
State Street6,3830 00For
Pacific Life6,2380 00For
John Hancock4,0800 00For
Invesco4,0080 00For
SEI3,9000 00For
Bridge Builder Trust3,3560 00For
Principal2,4940 00For
Voya2,1970 00For
T. Rowe Price1,4300 00For
Calvert1,3500 00For
ProShares8130 00For
Morgan Stanley6540 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

3. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to provide for exculpation of…

Outcome not verifiedCORPORATE GOVERNANCEReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 17,766,354AGAINST: 733,972
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Approval of an amendment to the Certificate of Incorporation to provide for the exculpation of officers to the extent permitted by the General Corporation Law of the State of Delaware.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“6. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to provide for exculpation of officers to the extent permitted by the General Corporation Law of the State of Delaware”): 17,766,354 for, 733,972 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,906,499 for, 33,614 against.

FOR
FOR: 1,906,499AGAINST: 33,614
Largest asset managers voting on “Approval of an amendment to the Certificate of Incorporation to provide for the exculpation of officers to the” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity562,9310 00For
Columbia Threadneedle505,2900 00For
Vanguard288,2440 00For
BlackRock262,5350 00For
Charles Schwab129,1690 00For
Equitable36,0560 00For
HC CAPITAL TRUST029,713 00Against
QUANTITATIVE MASTER SERIES LLC23,0640 00For
Northern Trust22,8230 00For
Lincoln Financial15,9300 00For
AIG/SunAmerica10,3150 00For
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds7,3140 00For
State Street6,3830 00For
Pacific Life6,2380 00For
John Hancock4,0800 00For
Invesco4,0080 00For
SEI03,900 00Against
Bridge Builder Trust3,3560 00For
Principal2,4940 00For
Voya2,1970 00For
T. Rowe Price1,4300 00For
Calvert1,3500 00For
ProShares8130 00For
Morgan Stanley6540 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

4. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to authorize additional shares of…

Outcome not verifiedCAPITAL STRUCTUREReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST
FOR: 21,154,462AGAINST: 4,882,353
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock of the Company from 100,000,000 to 200,000,000.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“5. Approval of an amendment to the Company's Certificate of Incorporation, as amended, to authorize additional shares of common stock from 100,000 to 200,000”): 21,154,462 for, 4,882,353 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,371,322 for, 568,791 against.

FORAGAINST
FOR: 1,371,322AGAINST: 568,791
Largest asset managers voting on “Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to in” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity135,592427,339 00Mixed
Columbia Threadneedle505,2900 00For
Vanguard288,2440 00For
BlackRock262,5350 00For
Charles Schwab0129,169 00Against
Equitable36,0560 00For
HC CAPITAL TRUST29,7130 00For
QUANTITATIVE MASTER SERIES LLC23,0640 00For
Northern Trust22,8230 00For
Lincoln Financial15,9300 00For
AIG/SunAmerica10,3150 00For
Federated Hermes08,382 00Against
Principal Exchange-Traded Funds7,3140 00For
State Street6,3830 00For
Pacific Life6,2380 00For
John Hancock4,0800 00For
Invesco4,0080 00For
SEI03,900 00Against
Bridge Builder Trust3,3560 00For
Principal2,4940 00For
Voya2,1970 00For
T. Rowe Price1,4300 00For
Calvert1,3500 00For
ProShares8130 00For
Morgan Stanley6540 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

5. Approval of an adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes at the…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST
FOR: 15,516,213AGAINST: 2,998,961
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 5 and/or 6.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“7. Approval of an adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal Nos. 5 and/or 6”): 15,516,213 for, 2,998,961 against — passed, per its Form 8-K filed June 12, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 7 — Approval of an adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal Nos. 5 and/or 6.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,355,361 for, 584,752 against.

FORAGAINST
FOR: 1,355,361AGAINST: 584,752
Largest asset managers voting on “Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity135,592427,339 00Mixed
Columbia Threadneedle505,2900 00For
Vanguard288,2440 00For
BlackRock262,5350 00For
Charles Schwab0129,169 00Against
Equitable36,0560 00For
HC CAPITAL TRUST29,7130 00For
QUANTITATIVE MASTER SERIES LLC23,0640 00For
Northern Trust22,8230 00For
Lincoln Financial015,930 00Against
AIG/SunAmerica10,3150 00For
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds7,3140 00For
State Street06,383 00Against
Pacific Life6,2380 00For
John Hancock4,0800 00For
Invesco4,0080 00For
SEI03,900 00Against
Bridge Builder Trust3,3560 00For
Principal2,4940 00For
Voya2,1970 00For
T. Rowe Price01,430 00Against
Calvert1,3500 00For
ProShares8130 00For
Morgan Stanley6540 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

6. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers…

Outcome not verifiedFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST
FOR: 14,391,943AGAINST: 4,123,997
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers ("Say-on-Pay Vote").

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers ("Say-on-Pay Vote")”): 14,391,943 for, 4,123,997 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 31 asset managers voting on “Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers ("” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity135,592427,339 00Mixed
Columbia Threadneedle0505,290 00Against
Vanguard288,2440 00For
BlackRock0262,535 00Against
Charles Schwab129,1690 00For
Equitable036,056 00Against
HC CAPITAL TRUST029,713 00Against
QUANTITATIVE MASTER SERIES LLC023,064 00Against
Northern Trust22,8230 00For
Lincoln Financial15,9300 00For
AIG/SunAmerica010,315 00Against
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds07,314 00Against
State Street6,3830 00For
Pacific Life06,238 00Against
John Hancock04,080 00Against
Invesco4,0080 00For
SEI3,9000 00For
Bridge Builder Trust03,356 00Against
Principal02,494 00Against
Voya02,197 00Against
T. Rowe Price01,430 00Against
Calvert01,350 00Against
ProShares0813 00Against
Morgan Stanley0654 00Against

Fund voting reports, all 31 managers: 615,032 for, 1,325,081 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 78 asset managers voting on “Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers ("” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARMISTICE CAPITAL, LLC3,090,0700 00For
Fidelity01,448,335 00Against
State Street438,3834,181 00For
BlackRock3,297380,438 00Against
GEODE CAPITAL MANAGEMENT, LLC160,9200 00For
MELLON INVESTMENTS Corp155,5200 00For
Northern Trust146,62695 00For
Charles Schwab129,1690 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC095,029 00Against
AMERIPRISE FINANCIAL INC073,074 00Against
TOCQUEVILLE ASSET MANAGEMENT L.P.042,943 00Against
AllianceBernstein029,990 00Against
Rhumbline010,932 00Against
Citadel21,5290 00For
PNC BANK, NATIONAL ASSOCIATION20,1070 00For
Goldman Sachs019,081 00Against
US BANK NATIONAL ASSOCIATION018,068 00Against
REGENTS OF THE UNIVERSITY OF CALIFORNIA014,200 00Against
TRUIST FINANCIAL CORP10,8790 00For
PRINCIPAL GLOBAL INVESTORS09,808 00Against
Invesco9,2440 00For
Federated Hermes8,3820 00For
Vanguard8,3130 00For
JPMorgan08,187 00Against
AQR05,878 00Against

Institutional-manager reports, all 78 managers: 4,230,864 for, 2,191,928 against, 10,932 1 year. Showing the 25 largest; every one is in the interactive database (link above).

7. Approval, on an advisory (non- binding) basis, of the frequency of future Say-on-Pay Votes.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

15% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: votes by 94 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 31 asset managers voting on “Approval, on an advisory (non- binding) basis, of the frequency of future Say-on-Pay Votes.” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
Columbia Threadneedle00 00--
Vanguard00 00--
BlackRock00 00--
Charles Schwab00 00--
Equitable00 00--
HC CAPITAL TRUST00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
Northern Trust00 00--
Lincoln Financial00 00--
AIG/SunAmerica00 00--
Federated Hermes00 00--
Principal Exchange-Traded Funds00 00--
State Street00 00--
Pacific Life00 00--
John Hancock00 00--
Invesco00 00--
SEI00 00--
Bridge Builder Trust00 00--
Principal00 00--
Voya00 00--
T. Rowe Price00 00--
Calvert00 00--
ProShares00 00--
Morgan Stanley00 00--

Fund voting reports, all 31 managers: 1,940,113 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 78 asset managers voting on “Approval, on an advisory (non- binding) basis, of the frequency of future Say-on-Pay Votes.” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARMISTICE CAPITAL, LLC00 00--
Fidelity00 00--
State Street00 00--
BlackRock00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
MELLON INVESTMENTS Corp00 00--
Northern Trust00 00--
Charles Schwab00 00--
PARAMETRIC PORTFOLIO ASSOCIATES LLC00 00--
AMERIPRISE FINANCIAL INC00 00--
TOCQUEVILLE ASSET MANAGEMENT L.P.00 00--
AllianceBernstein00 00--
Rhumbline010,932 00Against
Citadel00 00--
PNC BANK, NATIONAL ASSOCIATION00 00--
Goldman Sachs00 00--
US BANK NATIONAL ASSOCIATION00 00--
REGENTS OF THE UNIVERSITY OF CALIFORNIA00 00--
TRUIST FINANCIAL CORP00 00--
PRINCIPAL GLOBAL INVESTORS00 00--
Invesco00 00--
Federated Hermes00 00--
Vanguard00 00--
JPMorgan00 00--
AQR00 00--

Institutional-manager reports, all 78 managers: 2,000 for, 10,932 against, 6,419,924 1 year, 868 3 year. Showing the 25 largest; every one is in the interactive database (link above).

8. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 25,725,808AGAINST: 262,875
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024.

BIOXCEL THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 25,725,808 for, 262,875 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,940,113 for.

FOR
FOR: 1,940,113
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting” at BIOXCEL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity562,9310 00For
Columbia Threadneedle505,2900 00For
Vanguard288,2440 00For
BlackRock262,5350 00For
Charles Schwab129,1690 00For
Equitable36,0560 00For
HC CAPITAL TRUST29,7130 00For
QUANTITATIVE MASTER SERIES LLC23,0640 00For
Northern Trust22,8230 00For
Lincoln Financial15,9300 00For
AIG/SunAmerica10,3150 00For
Federated Hermes8,3820 00For
Principal Exchange-Traded Funds7,3140 00For
State Street6,3830 00For
Pacific Life6,2380 00For
John Hancock4,0800 00For
Invesco4,0080 00For
SEI3,9000 00For
Bridge Builder Trust3,3560 00For
Principal2,4940 00For
Voya2,1970 00For
T. Rowe Price1,4300 00For
Calvert1,3500 00For
ProShares8130 00For
Morgan Stanley6540 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Largest BIOXCEL THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,530,821 shares outstanding at the time of that meeting.

Fund voting reports: top BIOXCEL THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory (non-binding) basis, of the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 1.50%
2Columbia Threadneedle 1.35%
3Vanguard 0.77%
4BlackRock 0.70%
5Charles Schwab 0.34%
6Equitable 0.10%
7HC CAPITAL TRUST 0.08%
8QUANTITATIVE MASTER SERIES LLC 0.06%
9Northern Trust 0.06%
10Lincoln Financial 0.04%
Institutional-manager reports: top BIOXCEL THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory (non-binding) basis, of the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1ARMISTICE CAPITAL, LLC 8.23%
2Fidelity 3.86%
3State Street 1.18%
4BlackRock 1.02%
5GEODE CAPITAL MANAGEMENT, LLC 0.43%
6MELLON INVESTMENTS Corp 0.41%
7Northern Trust 0.39%
8Charles Schwab 0.34%
9PARAMETRIC PORTFOLIO ASSOCIATES LLC 0.25%
10AMERIPRISE FINANCIAL INC 0.19%

Reported BIOXCEL THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

BIOXCEL THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
Vimal Mehta, Ph.D. 23.76% DEF14A
BioXcel LLC 20.48% DEF14A
Oaktree Capital Group Holdings GP, LLC 7.26% 13G
Oaktree Capital Management, L.P. 7.26% DEF14A
Q Boost Holding LLC 7.26% DEF14A
Qatar Investment Authority 7.26% 13G
State Street 1.24% 13F
Peter Mueller, Ph.D. 1.22% DEF14A
Geode Capital 1.22% 13F
Armistice Capital, LLC 0.77% 13G

Percentages above are of 37,530,821 shares outstanding, as reported by BIOXCEL THERAPEUTICS INC. on its Form 10-Q dated May 7, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOXCEL THERAPEUTICS INC.’s 10-Q dated May 7, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

BIOXCEL THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).

Cite this page

proxyvotesnow.com, “BIOXCEL THERAPEUTICS (BTAIQ) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/bioxcel-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.